Physician profile
David J Brooks
NPI 1962440214
$575.20
in general payments reported to CMS, 2019-2025
13 companies · $54.78 in 2025
The $54.78 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.34 · 2021: $11.73 · 2022: $87.13 · 2023: $85.48 · 2024: $313 · 2025: $54.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $268.14 | 2024-2025 | Inspire |
| Pfizer INC. | $42.29 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $40.76 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $32.79 | 2022 | |
| Boston Scientific Corporation | $28.38 | 2022 | |
| Novo Nordisk INC | $28.09 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $25.96 | 2022 | |
| Indivior INC. | $21.74 | 2023 | Sublocade |
| Mallinckrodt Hospital Products INC. | $20.98 | 2023 | Terlivaz |
| Astellas Pharma US INC | $18.96 | 2024 | Veozah |
| Dexcom, INC. | $17.49 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $15.60 | 2023 | Vraylar |
| Sumitomo Pharma America, INC. | $14.02 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.